Companies in #Hematology
Found 2 companies operating in this sector.
Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company developing targeted C3 therapies to inhibit the complement cascade in diseases of hematology, ophthalmology, and nephrology. The company has two FDA-approved C3 inhibitors: Empaveli (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH), and Syfovre for geographic atrophy (GA) secondary to age-related macular degeneration.
Disc Medicine is a clinical-stage biopharmaceutical company developing novel hematology therapeutics for patients with serious and rare blood diseases. The company's pipeline includes bitopertin (a glycine transport-1 inhibitor) for erythropoietic protoporphyria (EPP) and other hematologic disorders.